Dianthus Hits Early GO Decision in Phase 3 CIDP Trial, Streamlines Path Forward
Event summary
- Dianthus achieved an early GO decision in its Phase 3 CAPTIVATE trial for claseprubart in CIDP, hitting 20 confirmed responders with fewer than 40 participants completing Part A.
- The company plans to maintain the 300mg/2mL S.C. Q2W dose in Part A and remove the 600mg/4mL S.C. Q2W dose arm from Part B after regulatory engagement.
- Dianthus will enroll up to 256 patients in Part A (down from 480) and randomize 128 patients in Part B (down from 192).
- No related serious infections, autoimmune activation, or serious adverse events were reported, confirmed by an independent DSMB review.
The big picture
Dianthus’ early GO decision in the CAPTIVATE trial positions claseprubart as a potential best-in-disease biologic for CIDP, targeting a broad patient population, including those refractory to standard-of-care treatments. The streamlined trial design could accelerate development timelines, but regulatory and execution risks remain. The company is also advancing claseprubart into other neuromuscular indications, expanding its pipeline-in-a-product strategy.
What we're watching
- Regulatory Dynamics
- Whether Dianthus can successfully remove the higher dose arm from Part B without delaying the trial timeline.
- Execution Risk
- The pace at which Dianthus can enroll the reduced number of patients in Part A and Part B.
- Market Positioning
- How claseprubart’s potential best-in-disease profile will compete in the multi-billion-dollar CIDP market.
Related topics